Kwan Lok Benjamin Ng, Yun-Nan Lin, Wei-Yu Chen, Yi-Chia Wu, Shu-Hung Huang, Su-Shin Lee, Rong-Fu Chen, Yur-Ren Kuo
{"title":"Enhancing diabetic foot wound healing with topical macrophage-regulating cream (ON101): a case series.","authors":"Kwan Lok Benjamin Ng, Yun-Nan Lin, Wei-Yu Chen, Yi-Chia Wu, Shu-Hung Huang, Su-Shin Lee, Rong-Fu Chen, Yur-Ren Kuo","doi":"10.12968/jowc.2023.0318","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>A number of treatments have been developed to treat hard-to-heal (chronic) diabetic foot ulcers (DFUs). This case series the use of ON101-a new topical macrophage regulatory cream for the treatment of DFUs, that helped achieve limb-salvage outcomes with an adequate safety profile.</p><p><strong>Method: </strong>Patients with hard-to-heal DFUs-primarily on the toes and plantar surfaces-were enrolled in the study. After infection control, wound debridement or angioplasty intervention, ON101, containing 1.25% extracts of <i>Plectranthus amboinicus</i> (0.25%) and <i>Centella asiatica</i> (1%), was applied topically to the wounds up to twice daily. The condition of the wounds, complications, healing progression and other details were documented.</p><p><strong>Results: </strong>In total, 10 patients, with a mean age of 59.2 years (range: 35-77 years), were included in the study following surgical debridement, sequestrectomy or revascularisation. Wound sizes ranged from 1-66 cm<sup>2</sup>. After receiving ON101 treatment for durations ranging from 14-264 days, most wounds healed without complications, except for one patient with osteomyelitis who did not fully recover. All patients expressed satisfaction with the outcomes and had no reported complications at the six-month follow-up.</p><p><strong>Conclusion: </strong>This case series demonstrated the real-world outcomes of ON101, which exhibited good healing efficacy in the treatment of DFUs, making it a promising strategy for the topical treatment of these ulcers.</p>","PeriodicalId":17590,"journal":{"name":"Journal of wound care","volume":"34 Sup8","pages":"lxxiv-lxxx"},"PeriodicalIF":1.7000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of wound care","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.12968/jowc.2023.0318","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: A number of treatments have been developed to treat hard-to-heal (chronic) diabetic foot ulcers (DFUs). This case series the use of ON101-a new topical macrophage regulatory cream for the treatment of DFUs, that helped achieve limb-salvage outcomes with an adequate safety profile.
Method: Patients with hard-to-heal DFUs-primarily on the toes and plantar surfaces-were enrolled in the study. After infection control, wound debridement or angioplasty intervention, ON101, containing 1.25% extracts of Plectranthus amboinicus (0.25%) and Centella asiatica (1%), was applied topically to the wounds up to twice daily. The condition of the wounds, complications, healing progression and other details were documented.
Results: In total, 10 patients, with a mean age of 59.2 years (range: 35-77 years), were included in the study following surgical debridement, sequestrectomy or revascularisation. Wound sizes ranged from 1-66 cm2. After receiving ON101 treatment for durations ranging from 14-264 days, most wounds healed without complications, except for one patient with osteomyelitis who did not fully recover. All patients expressed satisfaction with the outcomes and had no reported complications at the six-month follow-up.
Conclusion: This case series demonstrated the real-world outcomes of ON101, which exhibited good healing efficacy in the treatment of DFUs, making it a promising strategy for the topical treatment of these ulcers.
期刊介绍:
Journal of Wound Care (JWC) is the definitive wound-care journal and the leading source of up-to-date research and clinical information on everything related to tissue viability. The journal was first launched in 1992 and aimed at catering to the needs of the multidisciplinary team. Published monthly, the journal’s international audience includes nurses, doctors and researchers specialising in wound management and tissue viability, as well as generalists wishing to enhance their practice.
In addition to cutting edge and state-of-the-art research and practice articles, JWC also covers topics related to wound-care management, education and novel therapies, as well as JWC cases supplements, a supplement dedicated solely to case reports and case series in wound care. All articles are rigorously peer-reviewed by a panel of international experts, comprised of clinicians, nurses and researchers.
Specifically, JWC publishes:
High quality evidence on all aspects of wound care, including leg ulcers, pressure ulcers, the diabetic foot, burns, surgical wounds, wound infection and more
The latest developments and innovations in wound care through both preclinical and preliminary clinical trials of potential new treatments worldwide
In-depth prospective studies of new treatment applications, as well as high-level research evidence on existing treatments
Clinical case studies providing information on how to deal with complex wounds
Comprehensive literature reviews on current concepts and practice, including cost-effectiveness
Updates on the activities of wound care societies around the world.